Bristol Myers Squibb (BMY) After ZENBEXUS Approval Faces A Fully Valued Debate

Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval to ZENBEXUS, a first-in-class CELMoD therapy for adults with relapsed or refractory multiple myeloma.

The ZENBEXUS approval lands at a time when Bristol-Myers Squibb’s recent news flow also includes the end of its Cellares partnership for Breyanzi manufacturing and fresh questions around certain patent rights. Yet the share price has a 90-day return of 17.09% and a 1-year total shareholder return of 49.67%, suggesting momentum has been building rather than fading.

Spot emerging momentum stories alongside Bristol-Myers Squibb by scanning our hand picked 46 high quality undervalued stocks that pair strong cash flows with solid balance sheets.

After a near 50% 1 year total return and a strong run into the ZENBEXUS approval, Bristol-Myers Squibb now presents a clearer choice. Investors can either lean into the recent move or wait for a clearer margin of safety as valuation comes into focus next.

Most Popular Narrative: 6.3% Overvalued

The most followed narrative pegs Bristol-Myers Squibb’s fair value at $62.96, slightly below the last close at $66.95. This frames the current debate on how much of the ZENBEXUS news is already reflected in the price.

Robust late-stage pipeline and ongoing life-cycle management for major brands, plus strategic partnerships (BioNTech, Philochem, Bain), expand the breadth of future regulatory approvals and label expansions, opening additional indications and helping to offset upcoming patent expiries, which underpins top-line and earnings growth.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative still sees upside despite forecast revenue declines and higher discounting of risk? The key is how future margins, earnings power and valuation multiples are expected to interact. The detailed assumptions tell a much more nuanced story than the headline fair value number.

Result: Fair Value of $62.96 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Bristol-Myers Squibb narrative could still be knocked off course if upcoming patent cliffs bite harder than expected or if key late stage trials disappoint.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Another View on Bristol-Myers Squibb Valuation

The narrative fair value of $62.96 suggests Bristol-Myers Squibb is 6.3% above that target at $66.95. Yet on earnings multiples, the picture is very different. The stock trades on a P/E of 14.7x, while the estimated fair ratio is 18.3x and the US Pharmaceuticals industry averages 16.9x. That gap points to a potential valuation cushion rather than excess. The key question is which lens investors consider more informative when expectations shift next.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed signals around Bristol-Myers Squibb, it may be helpful to act promptly and review the full picture for yourself. Weigh both sides of the story with our breakdown of 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Bristol-Myers Squibb?

If you stop at Bristol-Myers Squibb, you might miss stocks that better fit your goals. Use focused screeners to uncover ideas that match your risk and return preferences.

• Target dependable income by reviewing companies with resilient payouts and balance sheets through our 12 dividend fortresses.
• Sharpen your focus on quality at a reasonable price with a carefully filtered set of 20 high quality undiscovered gems.
• Prioritise capital preservation and steadier returns by scanning a curated group of 76 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com